Cancer Research Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine Susan G. Komen for the Cure-AACR Outstanding Investigator Award for Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
[Cancer Research 57, 1116-1123, March 15, 1997]
© 1997 American Association for Cancer Research
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shih, C.
Right arrow Articles by Schultz, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shih, C.
Right arrow Articles by Schultz, R. M.

LY231514, a Pyrrolo[2,3-d]pyrimidine-based Antifolate That Inhibits Multiple Folate-requiring Enzymes

Chuan Shih1, Victor J. Chen, Lynn S. Gossett, Susan B. Gates, Warren C. MacKellar, Lillian L. Habeck, Katherine A. Shackelford, Lurane G. Mendelsohn, Daniel J. Soose, Vinod F. Patel, Sherri L. Andis, Jesse R. Bewley, Elizabeth A. Rayl, Barbara A. Moroson, G. Peter Beardsley, William Kohler, Manshan Ratnam and Richard M. Schultz

Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285 [C. S., V. J. C., L. S. G., S. B. G., W. C. M., L. L. H., K. A. S., L. G. M., D. J. S., V. F. P., S. L. A., J. R. B., R. M. S.]; Department of Pediatrics, Yale University, New Haven, Connecticut 06510 [E. A. R., B. A. M., G. P. B.]; and Department of Biochemistry and Molecular Biology, Medical College of Ohio, Toledo, Ohio 43699 [W. K., M. R.]

N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]-benzoyl]-L-glutamic acid (LY231514) is a novel pyrrolo[2,3-d]pyrimidine-based antifolate currently undergoing extensive Phase II clinical trials. Previous studies have established that LY231514 and its synthetic {gamma}-polyglutamates (glu3 and glu5) exert potent inhibition against thymidylate synthase (TS). We now report that LY231514 and its polyglutamates also markedly inhibit other key folate-requiring enzymes, including dihydrofolate reductase (DHFR) and glycinamide ribonucleotide formyltransferase (GARFT). For example, the Ki values of the pentaglutamate of LY231514 are 1.3, 7.2, and 65 nM for inhibition against TS, DHFR, and GARFT, respectively. In contrast, although a similar high level of inhibitory potency was observed for the parent monoglutamate against DHFR (7.0 nM), the inhibition constants (Ki) for the parent monoglutamate are significantly weaker for TS (109 nM) and GARFT (9,300 nM). The effects of LY231514 and its polyglutamates on aminoimidazole carboxamide ribonucleotide formyltransferase, 5,10-methylenetetrahydrofolate dehydrogenase, and 10-formyltetrahydrofolate synthetase were also evaluated. The end product reversal studies conducted in human cell lines further support the concept that multiple enzyme-inhibitory mechanisms are involved in cytotoxicity. The reversal pattern of LY231514 suggests that although TS may be a major site of action for LY231514 at concentrations near the IC50, higher concentrations can lead to inhibition of DHFR and/or other enzymes along the purine de novo pathway. Studies with mutant cell lines demonstrated that LY231514 requires polyglutamation and transport via the reduced folate carrier for cytotoxic potency. Therefore, our data suggest that LY231514 is a novel classical antifolate, the antitumor activity of which may result from simultaneous and multiple inhibition of several key folate-requiring enzymes via its polyglutamated metabolites.

1 To whom requests for reprints should be addressed, at Cancer Research Division, Lilly Research Laboratories, Drop 0540, Eli Lilly and Company, 307 E. McCarty St., Indianapolis, IN 46285. Phone: (317) 276-3520; Fax: (317) 277-3652.

Received 8/21/96. Accepted 1/17/97.




This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
F. Morgillo, E. Martinelli, T. Troiani, G. Laus, S. Pepe, C. Gridelli, and F. Ciardiello
Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase C{beta} inhibitor, in non-small cell lung cancer cells
Mol. Cancer Ther., June 1, 2008; 7(6): 1698 - 1707.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
E. Giovannetti, C. Lemos, C. Tekle, K. Smid, S. Nannizzi, J. A. Rodriguez, S. Ricciardi, R. Danesi, G. Giaccone, and G. J. Peters
Molecular Mechanisms Underlying the Synergistic Interaction of Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, with the Multitargeted Antifolate Pemetrexed in Non-Small-Cell Lung Cancer Cells
Mol. Pharmacol., April 1, 2008; 73(4): 1290 - 1300.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
S. Iwakiri, M. Sonobe, S. Nagai, T. Hirata, H. Wada, and R. Miyahara
Expression Status of Folate Receptor {alpha} Is Significantly Correlated with Prognosis in Non-Small-Cell Lung Cancers
Ann. Surg. Oncol., March 1, 2008; 15(3): 889 - 899.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. Chattopadhyay, R. Tamari, S. H. Min, R. Zhao, E. Tsai, and I. D. Goldman
Commentary: A Case for Minimizing Folate Supplementation in Clinical Regimens with Pemetrexed Based on the Marked Sensitivity of the Drug to Folate Availability
Oncologist, July 1, 2007; 12(7): 808 - 815.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Llombart-Cussac, M. Martin, N. Harbeck, R. M. Anghel, A. E. Eniu, M. W. Verrill, P. Neven, J. De Greve, A. S. Melemed, R. Clark, et al.
A Randomized, Double-Blind, Phase II Study of Two Doses of Pemetrexed as First-Line Chemotherapy for Advanced Breast Cancer
Clin. Cancer Res., June 15, 2007; 13(12): 3652 - 3659.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Li, Y.-H. Ling, I. D. Goldman, and R. Perez-Soler
Schedule-Dependent Cytotoxic Synergism of Pemetrexed and Erlotinib in Human Non-Small Cell Lung Cancer Cells
Clin. Cancer Res., June 1, 2007; 13(11): 3413 - 3422.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Malempati, H. S. Nicholson, J. M. Reid, S. M. Blaney, A. M. Ingle, M. Krailo, L. C. Stork, A. S. Melemed, R. McGovern, S. Safgren, et al.
Phase I Trial and Pharmacokinetic Study of Pemetrexed in Children With Refractory Solid Tumors: The Children's Oncology Group
J. Clin. Oncol., April 20, 2007; 25(12): 1505 - 1511.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S Boeck, K Weigang-Kohler, M Fuchs, E Kettner, D Quietzsch, J Trojan, O Stotzer, S Zeuzem, F Lordick, C-H Kohne, et al.
Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial
Ann. Onc., April 1, 2007; 18(4): 745 - 751.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Chattopadhyay, R. G. Moran, and I. D. Goldman
Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications
Mol. Cancer Ther., February 1, 2007; 6(2): 404 - 417.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Y. Seiwert, P. P. Connell, A. M. Mauer, P. C. Hoffman, C. M. George, L. Szeto, R. Salgia, K. E. Posther, B. Nguyen, D. J. Haraf, et al.
A Phase I Study of Pemetrexed, Carboplatin, and Concurrent Radiotherapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung or Esophageal Cancer
Clin. Cancer Res., January 15, 2007; 13(2): 515 - 522.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. K. Rowinsky, M. Beeram, L. A. Hammond, G. Schwartz, J. De Bono, B. Forouzesh, Q. Chu, J. E. Latz, S. Hong, W. John, et al.
A Phase I and Pharmacokinetic Study of Pemetrexed Plus Irinotecan in Patients with Advanced Solid Malignancies
Clin. Cancer Res., January 15, 2007; 13(2): 532 - 539.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Chattopadhyay, R. Zhao, E. Tsai, V. L. Schramm, and I. D. Goldman
The effect of a novel transition state inhibitor of methylthioadenosine phosphorylase on pemetrexed activity.
Mol. Cancer Ther., October 1, 2006; 5(10): 2549 - 2555.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
V. Garcia, J. M. Garcia, C. Pena, J. Silva, G. Dominguez, A. Hurtado, I. Alonso, R. Rodriguez, M. Provencio, and F. Bonilla
Thymidylate synthase messenger RNA expression in plasma from patients with colon cancer: prognostic potential.
Clin. Cancer Res., April 1, 2006; 12(7): 2095 - 2100.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Chattopadhyay, R. Zhao, S. A. Krupenko, N. Krupenko, and I. D. Goldman
The inverse relationship between reduced folate carrier function and Pemetrexed activity in a human colon cancer cell line.
Mol. Cancer Ther., February 1, 2006; 5(2): 438 - 449.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. X. Ma, P. Steen, K. M. Rowland, R. D. Niedringhaus, T. R. Fitch, J. W. Kugler, D. W. Hillman, E. A. Perez, J. N. Ingle, and A. A. Adjei
A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study
Ann. Onc., February 1, 2006; 17(2): 226 - 231.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Stark and Y. G. Assaraf
Loss of Sp1 function via inhibitory phosphorylation in antifolate-resistant human leukemia cells with down-regulation of the reduced folate carrier
Blood, January 15, 2006; 107(2): 708 - 715.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
H. Dai, Y. Chen, and W. F. Elmquist
Distribution of the Novel Antifolate Pemetrexed to the Brain
J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 222 - 229.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. X. Ma, S. Nair, S. Thomas, S. J. Mandrekar, D. A. Nikcevich, K. M. Rowland, T. R. Fitch, H. E. Windschitl, S. L. Hillman, S. E. Schild, et al.
Randomized Phase II Trial of Three Schedules of Pemetrexed and Gemcitabine As Front-Line Therapy for Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., September 1, 2005; 23(25): 5929 - 5937.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Beutel, H. Glen, P. Schoffski, J. Chick, S. Gill, J. Cassidy, and C. Twelves
Phase I Study of OSI-7904L, a Novel Liposomal Thymidylate Synthase Inhibitor in Patients with Refractory Solid Tumors
Clin. Cancer Res., August 1, 2005; 11(15): 5487 - 5495.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
E. Giovannetti, V. Mey, S. Nannizzi, G. Pasqualetti, L. Marini, M. Del Tacca, and R. Danesi
Cellular and Pharmacogenetics Foundation of Synergistic Interaction of Pemetrexed and Gemcitabine in Human Non-Small-Cell Lung Cancer Cells
Mol. Pharmacol., July 1, 2005; 68(1): 110 - 118.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N. Skacel, L. G. Menon, P. J. Mishra, R. Peters, D. Banerjee, J. R. Bertino, and E. E. Abali
Identification of Amino Acids Required for the Functional Up-regulation of Human Dihydrofolate Reductase Protein in Response to Antifolate Treatment
J. Biol. Chem., June 17, 2005; 280(24): 22721 - 22731.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. Dubey and J. H. Schiller
Three Emerging New Drugs for NSCLC: Pemetrexed, Bortezomib, and Cetuximab
Oncologist, April 1, 2005; 10(4): 282 - 291.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Hazarika, R. M. White Jr., B. P. Booth, Y.-C. Wang, D. Y. Lee Ham, C. Y. Liang, A. Rahman, J. V.S. Gobburu, N. Li, R. Sridhara, et al.
Pemetrexed in Malignant Pleural Mesothelioma
Clin. Cancer Res., February 1, 2005; 11(3): 982 - 992.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Zhao, S. Zhang, M. Hanscom, S. Chattopadhyay, and I. D. Goldman
Loss of Reduced Folate Carrier Function and Folate Depletion Result in Enhanced Pemetrexed Inhibition of Purine Synthesis
Clin. Cancer Res., February 1, 2005; 11(3): 1294 - 1301.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Zhao, S. Chattopadhyay, M. Hanscom, and I. D. Goldman
Antifolate Resistance in a HeLa Cell Line Associated With Impaired Transport Independent of the Reduced Folate Carrier
Clin. Cancer Res., December 15, 2004; 10(24): 8735 - 8742.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Chattopadhyay, Y. Wang, R. Zhao, and I. D. Goldman
Lack of Impact of the Loss of Constitutive Folate Receptor {alpha} Expression, Achieved by RNA Interference, on the Activity of the New Generation Antifolate Pemetrexed in HeLa Cells
Clin. Cancer Res., December 1, 2004; 10(23): 7986 - 7993.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
L. Rothem, M. Stark, and Y. G. Assaraf
Impaired CREB-1 Phosphorylation in Antifolate-Resistant Cell Lines with Down-Regulation of the Reduced Folate Carrier Gene
Mol. Pharmacol., December 1, 2004; 66(6): 1536 - 1543.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. Pistolesi and J. Rusthoven
Malignant Pleural Mesothelioma: Update, Current Management, and Newer Therapeutic Strategies
Chest, October 1, 2004; 126(4): 1318 - 1329.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Wang, R. Zhao, and I. D. Goldman
Characterization of a Folate Transporter in HeLa Cells with a Low pH Optimum and High Affinity for Pemetrexed Distinct from the Reduced Folate Carrier
Clin. Cancer Res., September 15, 2004; 10(18): 6256 - 6264.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Hazarika, R. M. White, J. R. Johnson, and R. Pazdur
FDA Drug Approval Summaries: Pemetrexed (Alimta(R))
Oncologist, September 1, 2004; 9(5): 482 - 488.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Monnerat, T. Le Chevalier, K. Kelly, C. K. Obasaju, J. Brahmer, S. Novello, T. Nakamura, A. M. Liepa, L. Bozec, P. A. Bunn Jr, et al.
Phase II Study of Pemetrexed-Gemcitabine Combination in Patients with Advanced-Stage Non-Small Cell Lung Cancer
Clin. Cancer Res., August 15, 2004; 10(16): 5439 - 5446.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. L. Misset, E. Gamelin, M. Campone, S. Delaloge, J. E. Latz, L. Bozec, and P. Fumoleau
Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors
Ann. Onc., July 1, 2004; 15(7): 1123 - 1129.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. A. Adjei
Pemetrexed (ALIMTA), A Novel Multitargeted Antineoplastic Agent
Clin. Cancer Res., June 15, 2004; 10(12): 4276S - 4280S.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
I. Ifergan, A. Shafran, G. Jansen, J. H. Hooijberg, G. L. Scheffer, and Y. G. Assaraf
Folate Deprivation Results in the Loss of Breast Cancer Resistance Protein (BCRP/ABCG2) Expression: A ROLE FOR BCRP IN CELLULAR FOLATE HOMEOSTASIS
J. Biol. Chem., June 11, 2004; 279(24): 25527 - 25534.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. Zhao and I. D. Goldman
Enter Alimta(R): A New Generation Antifolate
Oncologist, June 1, 2004; 9(3): 242 - 244.
[Full Text] [PDF]

Home page
 The OncologistHome page
E. Diaz-Rubio
New Chemotherapeutic Advances in Pancreatic, Colorectal, and Gastric Cancers
Oncologist, June 1, 2004; 9(3): 282 - 294.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. B. Longley, W. L. Allen, U. McDermott, T. R. Wilson, T. Latif, J. Boyer, M. Lynch, and P. G. Johnston
The Roles of Thymidylate Synthase and p53 in Regulating Fas-Mediated Apoptosis in Response to Antimetabolites
Clin. Cancer Res., May 15, 2004; 10(10): 3562 - 3571.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Zhao, M. Hanscom, S. Chattopadhyay, and I. D. Goldman
Selective Preservation of Pemetrexed Pharmacological Activity in HeLa Cells Lacking the Reduced Folate Carrier: Association with the Presence of a Secondary Transport Pathway
Cancer Res., May 1, 2004; 64(9): 3313 - 3319.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Giovannetti, V. Mey, R. Danesi, I. Mosca, and M. Del Tacca
Synergistic Cytotoxicity and Pharmacogenetics of Gemcitabine and Pemetrexed Combination in Pancreatic Cancer Cell Lines
Clin. Cancer Res., May 1, 2004; 10(9): 2936 - 2943.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. Rothem, M. Stark, Y. Kaufman, L. Mayo, and Y. G. Assaraf
Reduced Folate Carrier Gene Silencing in Multiple Antifolate-resistant Tumor Cell Lines Is Due to a Simultaneous Loss of Function of Multiple Transcription Factors but Not Promoter Methylation
J. Biol. Chem., January 2, 2004; 279(1): 374 - 384.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Martin, M. Spielmann, M. Namer, A. duBois, C. Unger, D. Dodwell, P. Vodvarka, M. Lind, H. Calvert, A. Casado, et al.
Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines
Ann. Onc., August 1, 2003; 14(8): 1246 - 1252.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. J. Vogelzang, J. J. Rusthoven, J. Symanowski, C. Denham, E. Kaukel, P. Ruffie, U. Gatzemeier, M. Boyer, S. Emri, C. Manegold, et al.
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
J. Clin. Oncol., July 15, 2003; 21(14): 2636 - 2644.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. S. Theti, V. Bavetsias, L. A. Skelton, J. Titley, D. Gibbs, G. Jansen, and A. L. Jackman
Selective Delivery of CB300638, a Cyclopenta[g]quinazoline-based Thymidylate Synthase Inhibitor into Human Tumor Cell Lines Overexpressing the {alpha}-Isoform of the Folate Receptor
Cancer Res., July 1, 2003; 63(13): 3612 - 3618.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
P. Wells, E. Aboagye, R. N. Gunn, S. Osman, A. V. Boddy, G. A. Taylor, I. Rafi, A. N. Hughes, A. H. Calvert, P. M. Price, et al.
2-[11C]Thymidine Positron Emission Tomography as an Indicator of Thymidylate Synthase Inhibition in Patients Treated With AG337
J Natl Cancer Inst, May 7, 2003; 95(9): 675 - 682.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. V. Scagliotti, D.-M. Shin, H. L. Kindler, M. J. Vasconcelles, U. Keppler, C. Manegold, H. Burris, U. Gatzemeier, J. Blatter, J. T. Symanowski, et al.
Phase II Study of Pemetrexed With and Without Folic Acid and Vitamin B12 as Front-Line Therapy in Malignant Pleural Mesothelioma
J. Clin. Oncol., April 15, 2003; 21(8): 1556 - 1561.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. Rothem, A. Aronheim, and Y. G. Assaraf
Alterations in the Expression of Transcription Factors and the Reduced Folate Carrier as a Novel Mechanism of Antifolate Resistance in Human Leukemia Cells
J. Biol. Chem., March 7, 2003; 278(11): 8935 - 8941.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. J. Allegra, S. Paik, L. H. Colangelo, A. L. Parr, I. Kirsch, G. Kim, P. Klein, P. G. Johnston, N. Wolmark, and H. S. Wieand
Prognostic Value of Thymidylate Synthase, Ki-67, and p53 in Patients With Dukes' B and C Colon Cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study
J. Clin. Oncol., January 15, 2003; 21(2): 241 - 250.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Wang, R. Zhao, S. Chattopadhyay, and I. D. Goldman
A Novel Folate Transport Activity in Human Mesothelioma Cell Lines with High Affinity and Specificity for the New-Generation Antifolate, Pemetrexed
Cancer Res., November 15, 2002; 62(22): 6434 - 6437.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Hughes, P. Calvert, A. Azzabi, R. Plummer, R. Johnson, J. Rusthoven, M. Griffin, K. Fishwick, A. V Boddy, M. Verrill, et al.
Phase I Clinical and Pharmacokinetic Study of Pemetrexed and Carboplatin in Patients With Malignant Pleural Mesothelioma
J. Clin. Oncol., August 15, 2002; 20(16): 3533 - 3544.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. J. Clarke, R. Abratt, L. Goedhals, M. J. Boyer, M. J. Millward, and S. P. Ackland
Phase II trial of pemetrexed disodium (ALIMTA(R), LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer
Ann. Onc., May 1, 2002; 13(5): 737 - 741.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. J. Allegra, A. L. Parr, L. E. Wold, M. R. Mahoney, D. J. Sargent, P. Johnston, P. Klein, K. Behan, M. J. O'Connell, R. Levitt, et al.
Investigation of the Prognostic and Predictive Value of Thymidylate Synthase, p53, and Ki-67 in Patients With Locally Advanced Colon Cancer
J. Clin. Oncol., April 1, 2002; 20(7): 1735 - 1743.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Tesei, L. Ricotti, F. D. Paola, D. Amadori, G. L. Frassineti, and W. Zoli
In Vitro Schedule-dependent Interactions between the Multitargeted Antifolate LY231514 and Gemcitabine in Human Colon Adenocarcinoma Cell Lines
Clin. Cancer Res., January 1, 2002; 8(1): 233 - 239.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. B. Longley, P. R. Ferguson, J. Boyer, T. Latif, M. Lynch, P. Maxwell, D. P. Harkin, and P. G. Johnston
Characterization of a Thymidylate Synthase (TS)-inducible Cell Line: A Model System for Studying Sensitivity to TS- and non-TS-targeted Chemotherapies
Clin. Cancer Res., November 1, 2001; 7(11): 3533 - 3539.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A.-R. Hanauske, V. Chen, P. Paoletti, and C. Niyikiza
Pemetrexed Disodium: A Novel Antifolate Clinically Active Against Multiple Solid Tumors
Oncologist, August 1, 2001; 6(4): 363 - 373.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. G. Smith, H. D. Thomas, H. C. Barlow, R. J. Griffin, B. T. Golding, A. H. Calvert, D. R. Newell, and N. J. Curtin
In Vitro and in Vivo Properties of Novel Nucleoside Transport Inhibitors with Improved Pharmacological Properties That Potentiate Antifolate Activity
Clin. Cancer Res., July 1, 2001; 7(7): 2105 - 2113.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
X. Lu, J. Errington, N. J. Curtin, J. Lunec, and D. R. Newell
The Impact of p53 Status on Cellular Sensitivity to Antifolate Drugs
Clin. Cancer Res., July 1, 2001; 7(7): 2114 - 2123.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. L. van der Wilt, H. H. J. Backus, K. Smid,